Prev Close | 268.35 |
Open | 265.51 |
Day Low/High | 263.78 / 268.00 |
52 Wk Low/High | 176.36 / 292.75 |
Volume | 481.17K |
Prev Close | 268.35 |
Open | 265.51 |
Day Low/High | 263.78 / 268.00 |
52 Wk Low/High | 176.36 / 292.75 |
Volume | 481.17K |
Exchange | NASDAQ |
Shares Outstanding | 255.76B |
Market Cap | 66.14B |
P/E Ratio | 23.27 |
Div & Yield | N.A. (N.A) |
Here is this week's roundup of the dumbest actions on Wall Street.
The longer this action persists, the more anxious folks will be to put idle cash to work.
SPDR S&P Biotech ETF is likely to post new highs in the second quarter.
Evan Lazarus of T3Live review the day's market action and sets up your trading plan for the next session.
Senior columnist Adam Feuerstein says Pfizer is the next big thing in biotech.
Here are a couple of window-dressing plays as we head into the end of the quarter.
Earnings season is well upon us, so better to be prepared than, well, taken by surprise.
Based on patterns of estimates revisions, these names might just generate some magic when they report.
Here is my take on some questions from readers.
Because of Europe, the market has turned a deaf ear toward earnings season.
The euro/dollar cross foretold yesterday's big rally, but individual stocks' action amid the broad upswing could be telling.
The chart and the CEO tell very different stories about the drugmaker. Which one is right?